Insulin glargine and lixisenatide Subcutaneous and Ranibizumab ophthalmic
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Ranibizumab ophthalmic and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: ranibizumab ophthalmic
Brand name: Lucentis
Synonyms: Ranibizumab (ophthalmic), Ranibizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Ranitidine
- Insulin glargine and lixisenatide Subcutaneous-Ranitidine Capsule
- Insulin glargine and lixisenatide Subcutaneous-Ranitidine Hydrochloride
- Insulin glargine and lixisenatide Subcutaneous-Ranitidine Injection
- Insulin glargine and lixisenatide Subcutaneous-Ranitidine Suspension
- Insulin glargine and lixisenatide Subcutaneous-Ranitidine Syrup
- Ranibizumab ophthalmic-Insulin glargine, recombinant Subcutaneous
- Ranibizumab ophthalmic-Insulin glulisine
- Ranibizumab ophthalmic-Insulin Glulisine (Cartridges and Pens)
- Ranibizumab ophthalmic-Insulin Glulisine (Vials)
- Ranibizumab ophthalmic-Insulin glulisine Subcutaneous
- Ranibizumab ophthalmic-Insulin human inhaled Inhalation